Long-Term Infectious Complications and Their Relation to Treatment Duration in Catheter-Related Staphylococcus aureus Bacteremia

2001 ◽  
Vol 20 (6) ◽  
pp. 0380-0384 ◽  
Author(s):  
M. M. P. Zeylemaker ◽  
C. A. J. J. Jaspers ◽  
M.G.J. van Kraaij ◽  
M. R. Visser ◽  
I. M. Hoepelman
Keyword(s):  
Staphylococcus Aureus ◽  
Treatment Duration ◽  
Infectious Complications ◽  
Staphylococcus Aureus Bacteremia

Comparable Outcomes of Short-Course and Prolonged-Course Therapy in Selected Cases of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Pooled Cohort Study

2021 ◽  
Author(s):  
Louise Thorlacius-Ussing ◽  
Håkon Sandholdt ◽  
Jette Nissen ◽  
Jon Rasmussen ◽  
Robert Skov ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Clinical Outcomes ◽  
Treatment Duration ◽  
Cohort Analysis ◽  
Antimicrobial Treatment ◽  
Low Risk ◽  
Logistic Regression Models ◽  
Staphylococcus Aureus Bacteremia ◽  
Short Course ◽  
The Individual

Abstract Background The recommended duration of antimicrobial treatment for Staphylococcus aureus bacteremia (SAB) is a minimum of 14 days. We compared the clinical outcomes of patients receiving short-course (SC; 6–10 days), or prolonged-course (PC; 11–16 days) antibiotic therapy for low-risk methicillin-susceptible SAB (MS-SAB). Methods Adults with MS-SAB in 1995–2018 were included from 3 independent retrospective cohorts. Logistic regression models fitted with inverse probability of treatment weighting were used to assess the association between the primary outcome of 90-day mortality and treatment duration for the individual cohorts as well as a pooled cohort analysis. Results A total of 645, 219, and 141 patients with low-risk MS-SAB were included from cohorts I, II, and III. Median treatment duration in the 3 SC groups was 8 days (interquartile range [IQR], 7–10), 9 days (IQR, 8–10), and 8 days (IQR, 7–10). In the PC groups, patients received a median therapy of 14 days (IQR, 13–15), 14 days (IQR, 13–15), and 13 days (IQR, 12–15). No significant differences in 90-day mortality were observed between the SC and PC group in cohort I (odds ratio [OR], 0.85 [95% confidence interval {CI}, .49–1.41]), cohort II (OR, 1.24 [95% CI, .60–2.62]), or cohort III (OR, 1.15 [95% CI, .24–4.01]). This result was consistent in the pooled cohort analysis (OR, 1.05 [95% CI, .71–1.51]). Furthermore, duration of therapy was not associated with the risk of relapse. Conclusions In patients with low-risk MS-SAB, shorter courses of antimicrobial therapy yielded similar clinical outcomes as longer courses of therapy.

scholarly journals Influence of Acetylsalicylic Acid Use on Risk and Outcome of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Study

2019 ◽  
Vol 6 (9) ◽  
Author(s):  
Jesper Smit ◽  
Michael Dalager-Pedersen ◽  
Kasper Adelborg ◽  
Achim J Kaasch ◽  
Reimar W Thomsen ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Acetylsalicylic Acid ◽  
Population Based ◽  
Socioeconomic Indicators ◽  
Medical Databases ◽  
Staphylococcus Aureus Bacteremia ◽  
Increased Risk ◽  
First Time ◽  
Population Controls

Abstract Objective To investigate the influence of acetylsalicylic acid (ASA) use on risk and outcome of community-acquired Staphylococcus aureus bacteremia (CA-SAB). Method We used population-based medical databases to identify all patients diagnosed in northern Denmark with first-time CA-SAB and matched population controls from 2000–2011. Categories for ASA users included current users (new or long-term users), former users, and nonusers. The analyses were adjusted for comorbidities, comedication use, and socioeconomic indicators. Results We identified 2638 patients with first-time CA-SAB and 26 379 matched population controls. Compared with nonusers, the adjusted odds ratio (aOR) for CA-SAB was 1.00 (95% confidence interval [CI], 0.88–1.13) for current users, 1.00 (95% CI, 0.86–1.16) for former users, 2.04 (95% CI, 1.42–2.94) for new users, and 0.95 (95% CI, 0.84–1.09) for long-term users. Thirty-day cumulative mortality was 28.0% among current users compared with 21.6% among nonusers, yielding an adjusted hazard rate ratio (aHRR) of 1.02 (95% CI, 0.84–1.25). Compared with nonusers, the aHRR was 1.10 (95% CI, 0.87–1.40) for former users, 0.60 (95% CI, 0.29–1.21) for new users, and 1.06 (95% CI, 0.87–1.31) for long-term users. We observed no difference in the risk or outcome of CA-SAB with increasing ASA dose or by presence of diseases commonly treated with ASA. Conclusions Use of ASA did not seem to influence the risk or outcome of CA-SAB. The apparent increased risk among new users may relate to residual confounding from the circumstances underlying ASA treatment initiation. Our finding of no association remained robust with increasing ASA dose and across multiple patient subsets.

scholarly journals Immune Dysfunction Prior to Staphylococcus aureus Bacteremia Is a Determinant of Long-Term Mortality

PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e88197 ◽  
Author(s):  
Jared A. Greenberg ◽  
Michael Z. David ◽  
Jesse B. Hall ◽  
John P. Kress
Keyword(s):  
Staphylococcus Aureus ◽  
Immune Dysfunction ◽  
Staphylococcus Aureus Bacteremia ◽  
Long Term Mortality

scholarly journals Association of Infectious Diseases Consultation With Long-term Postdischarge Outcomes Among Patients With Staphylococcus aureus Bacteremia

2020 ◽  
Vol 3 (2) ◽  
pp. e1921048
Author(s):  
Michihiko Goto ◽  
Michael P. Jones ◽  
Marin L. Schweizer ◽  
Daniel J. Livorsi ◽  
Eli N. Perencevich ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Infectious Diseases ◽  
Staphylococcus Aureus Bacteremia ◽  
Infectious Diseases Consultation

scholarly journals Clinical Reasoning of Infectious Diseases Physicians Behind the Use or Nonuse of Transesophageal Echocardiography in Staphylococcus aureus Bacteremia

2016 ◽  
Vol 3 (4) ◽  
Author(s):  
Heather Young ◽  
Bryan C. Knepper ◽  
Connie S. Price ◽  
Susan Heard ◽  
Timothy C. Jenkins
Keyword(s):  
Staphylococcus Aureus ◽  
Infectious Diseases ◽  
Transesophageal Echocardiography ◽  
Clinical Reasoning ◽  
Prospective Cohort ◽  
Treatment Duration ◽  
Blood Cultures ◽  
Extended Treatment ◽  
Staphylococcus Aureus Bacteremia ◽  
Rapid Clearance

Abstract In this prospective cohort with Staphylococcus aureus bacteremia, transesophageal echocardiography (TEE) was performed in 24% of cases. Consulting Infectious Diseases physicians most frequently cited low suspicion for endocarditis due to rapid clearance of blood cultures and the presence of a secondary focus requiring an extended treatment duration as reasons for foregoing TEE.

scholarly journals Uncomplicated Staphylococcus aureus Bacteremia Treatment Duration and Outcomes at an Academic Medical Center

2020 ◽  
Vol 7 (10) ◽  
Author(s):  
Daniel Taupin ◽  
Adolf W Karchmer ◽  
Roger B Davis ◽  
Mary T LaSalvia
Keyword(s):  
Staphylococcus Aureus ◽  
Treatment Duration ◽  
Medical Center ◽  
Academic Medical Center ◽  
Vein Thrombosis ◽  
Duration Of Therapy ◽  
Staphylococcus Aureus Bacteremia ◽  
Academic Medical ◽  
Intravenous Antibiotics ◽  
Deep Vein

Abstract We compared outcomes and clinical characteristics of uncomplicated Staphylococcus aureus bacteremia planned for a 14-day or >14-day course of intravenous antibiotics. Treatment failure was infrequent in both groups (0% and 5%, respectively). Catheter-associated deep vein thrombosis, immunosuppression, and valvular dysfunction were associated with a longer planned duration of therapy.

Sign in / Sign up

Export Citation Format

Share Document